Krystal Biotech, Inc. (KRYS) Institutional Ownership

Ownership Summary

Krystal Biotech, Inc. (NASDAQ:KRYS) showed up in the 13F filings of 361 institutional investors as of March 2026.

• Collectively, these holders controlled 97.6% of Krystal Biotech's outstanding shares in March 2026, down from 107.6% in December 2025.
• They increased total shares held in Krystal Biotech by 2.9% from last quarter, and the number of investors in KRYS increased 19.14% annually.
• Of these 361 holders, 213 added to their stakes in Krystal Biotech, 103 trimmed positions, and 45 made no changes.
• Institutional investors collectively held 28.59Mn shares in Krystal Biotech as of March 2026, up by 805.67K shares quarter on quarter, and down 231.16K shares year over year.
• FMR LLC holds the largest position in KRYS at 4.37Mn shares as of March 31, 2026, or 14.93% of shares outstanding.
• Top purchasers of KRYS stock for the quarter ending March 2026 included VANGUARD PORTFOLIO MANAGEMENT LLC (1.46Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.17Mn), PRICE T ROWE ASSOCIATES INC /MD/ (485.07K), Janus Henderson Group Plc (313.88K), Soleus Capital Management, L.P. (212.03K).
• The biggest sellers of Krystal Biotech for the quarter ending March 2026 included Avoro Capital Advisors LLC (2.89Mn), CITADEL ADVISORS LLC (383.78K), Goldman Sachs Group Inc (372.1K), MARSHALL WACE, LLP (115.41K), Corient Private Wealth LLC (73.11K).
• Per Business Quant data, the top 10 holders of Krystal Biotech for the quarter ending March 2026 are FMR LLC (4.37Mn), BlackRock, Inc. (3.94Mn), Avoro Capital Advisors LLC (2.89Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (1.46Mn), State Street Corp (1.31Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.17Mn), Soleus Capital Management, L.P. (1.15Mn), Capital World Investors (824.72K), Redmile Group, LLC (673.5K), GEODE CAPITAL MANAGEMENT, LLC (643.98K).